Challenges and methodology in the incorporation of biomarkers in cancer clinical trials

详细信息    查看全文

• 作者：Charlotte S. Wilhelm-Benartzi^a ; ^b ; ^{c.wilhelm-benartzi@imperial.ac.uk} ; ^{charlottewilhelm@gmail.com}Author Vitae ; Shahrul Mt-Isa^bAuthor Vitae ; Francesca Fiorentino^bAuthor Vitae ; Robert Brown^cAuthor Vitae ; Deborah Ashby^bAuthor Vitae
• 关键词：Clinical trials ; Biomarkers ; Research design ; Statistical ; Cancer
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：110
• 期：Complete
• 页码：49-61
• 全文大小：736 K
• 卷排序：110

文摘

Biomarkers can be used to establish more homogeneous groups using the genetic makeup of the tumour to inform the selection of treatment for each individual patient. However, proper preclinical work and stringent validation are needed before taking forward biomarkers into confirmatory studies. Despite the challenges, incorporation of biomarkers into clinical trials could better target appropriate patients, and potentially be lifesaving. The authors conducted a systematic review to describe marker-based and adaptive design methodology for their integration in clinical trials, and to further describe the associated practical challenges. Studies published between 1990 to November 2015 were searched on PubMed. Titles, abstracts and full text articles were reviewed to identify relevant studies. Of the 4438 studies examined, 57 studies were included. The authors conclude that the proposed approaches may readily help researchers to design biomarker trials, but novel approaches are still needed.